Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966003 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 642
- Enrollment target
NCT01966003 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 642 participants.
The verdict
NCT01966003, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 642 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG ABP 215
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 642 participants |
| Start Date | 2013-11-11 |
| Est. Completion | 2015-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01966003
The ClinicalTrials.gov registry entry for NCT01966003 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 642 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01966003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01966003 about?
NCT01966003 is a clinical study titled "Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
What is the current status of trial NCT01966003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 642 participants. The study started on 2013-11-11. Estimated completion is 2015-07-23.
What interventions are being tested in trial NCT01966003?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), ABP 215 (DRUG).
Who is sponsoring clinical trial NCT01966003?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.